LIU, Qi; HOU, Lingli; ZHAO, Ying; YANG, Hongwei; MO, Zhengying; YU, Fei. Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer. Clinics, São Paulo, Brasil, v. 78, p. 100291, 2023. DOI: 10.1016/. Disponível em: https://revistas.usp.br/clinics/article/view/236619.. Acesso em: 10 nov. 2025.